TPG Looking To Sell Canadian Drugmaker For $3B
Private equity firm TPG Capital LP is considering a sale of Aptalis Pharma Inc., a Montreal-based drugmaker focused on the treatment of gastrointestinal disorders, for more than $3 billion, according to...To view the full article, register now.
Already a subscriber? Click here to view full article